Chemical genomics as an emerging paradigm for postgenomic drug discovery

Abstract

Chemical genomics approaches are evolving to overcome key problems limiting the efficiency of drug discovery in the postgenomic era. Many of these stem from the low success rates in finding drugs for novel genomics targets whose biochemical properties and therapeutic relevance is poorly understood. The fundamental objective of chemical genomics is to find and optimize chemical compounds that can be used to directly test the therapeutic relevance of new targets revealed through genome sequencing. An integrated approach to chemical genomics encompasses a diverse set of tools including quantitative affinity-based screens, computer-directed combinatorial chemistry, and structure-based drug design. The approach is most effectively applied across targets classes whose members are structurally related, and where some members are known to have bona fide therapeutic relevance.